← Human Trials & Peer-Reviewed Studies
Effects of terlipressin infusion during hepatobiliary surgery on systemic and splanchnic haemodynamics, renal function and blood loss: a double-blind, randomized clinical trial
Plain-language guide to PMID 31200638 (2019): double-blind randomized controlled trial study of Terlipressin in 50 patients.
Key Facts
- PMID
- 31200638
- Journal
- BMC anesthesiology
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Mahdy MM et al. (13 authors)
- DOI
- 10.1186/s12871-019-0779-6
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Terlipressin, published as a randomized controlled trial.
The primary outcome was to assess the impact of intraoperative terlipressin infusion on portal venous pressure during hepatobiliary surgery; the 2ry outcomes included effects upon systemic hemodynamics, estimated blood loss, and postoperative renal functions.
Why It Was Studied
Terlipressin, in general, is a vasopressor which acts via V1 receptors.
Clinical trial number and registry URL: Trial registration number: NCT02718599 .
Who Took Part
According to the abstract, 50 patients were involved.
PubMed indexes the participants as middle-aged adults, both men and women.
This prospective randomized study involved 50 patients undergoing hepatobiliary surgery who were randomly and equally allocated into terlipressin group, or a control group.
How the Study Was Run
The design is described as randomized and double-blind.
Random assignment meant chance, not the researchers, decided who got Terlipressin and who got the comparison, which limits bias.
Blinding on both sides kept the patients and researchers unaware of who received Terlipressin.
The portal venous pressure changes were measured directly through a portal vein angiocatheter.
What Was Measured
Topics PubMed links to this paper include Digestive System Diseases, Hemodynamics, Hemorrhage, Kidney Function Tests, Terlipressin and Vasoconstrictor Agents.
The authors tagged it with the keywords Blood loss and Portal pressure.
What This Means in Plain Language
The paper is a randomized and double-blind study of Terlipressin in 50 patients.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (BMC anesthesiology), a journal based in England.
More context: the Terlipressin compound page, all human trials.
Our Notes on the Compound
Terlipressin: A synthetic vasopressin analog (Terlivaz) used for kidney failure in advanced liver disease and for variceal bleeding.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.